Immunomedics (IMMU) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gustav G. Widmayer who wrote (250)	12/3/1999 1:14:00 PM
From: David Moyer	of 371

Well we are back to 3 again. This is a sleeper that is waking up. Not only do we have 50% of 70% in remission for lymphoma who failed on chemo, bone marrow transplant and another product from a well capitalized biotech firm, we also have a way to deliver agents to the site. When a NY Times article stated that angiostatin (Entremed) had "cured" rats of cancer the stock rose from 20 to 80 in one day. It is now in the 20's again. Lets assume that angiostatin works, and prevents the development of blood vessels to tumors. I am not a technical person but it would appear logical that cutting off the blood flow to a tumor systemically would also prevent the body creating blood vessels to heal itself. But if the angiostatin is targeted with one of tools IMMU has then there would be no systemic impairment of the body's ability to creat new blood vessels. Not that IMMU needs angiostatin. It appears their CEA antibody plus radiological and chemical agents attached to the antibody provides a decent enough kill ratio for tumors. Would be interested in comments from anyone in the field given that my observations are based on intuition and not technical expertise.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next